Muted Q2 But Biocon Confident Of Insulin Glargine’s Onward US March

 
• By Anju Ghangurde

Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.

A man is building a ladder or growth chart from blocks. Strategy planning business expansion. Climbing the career ladder. Increase in income, organization of processors. Prioritization. Leadership
Long Revenue Stream Expected For Biocon-Mylan's Lantus Follow-On • Source: Shutterstock

More from Business

More from Scrip